Merck KGaA, Darmstadt, Germany Signs Definitive Agreement to Acquire Rapid Micro Biosystems, Advancing Automation in Pharmaceutical Quality Control
Key Highlights
- ➤Merck KGaA agrees to acquire Rapid Micro Biosystems for US$ 0.75 per share in cash
- ➤Transaction expected to close in December 2026, subject to customary conditions
- ➤Growth Direct automates microbial testing, including incubation, imaging and colony counting
- ➤Acquisition strengthens Merck’s integrated pharmaceutical quality-control workflow offering
- ➤Rapid Micro Biosystems shareholders must tender at least a majority of outstanding voting shares
Expert Statements
Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany
“Quality control is essential to the reliable manufacture of medicines. Our customers need reliable results faster, more efficient quality-control workflows and robust data integrity to support regulatory compliance. Rapid Micro Biosystems will strengthen our ability to meet those needs, building on our existing offering and bringing greater automation to a critical step in pharmaceutical manufacturing.”
Robert Spignesi, President and CEO of Rapid Micro Biosystems
“Joining Merck KGaA, Darmstadt, Germany will give us the opportunity to combine our expertise in automation with a broader range of quality-control workflow solutions. Our collective capabilities and deep understanding of pharmaceutical manufacturing and quality control will enable us to more fully serve our combined global customer base.”
Darmstadt, Germany, Nov. 16, 2026 (GLOBE NEWSWIRE) -- * Proposed acquisition would strengthen company’s quality-control workflow offering with Rapid Micro Biosystems’ Growth Direct(®) automated microbial quality-control platform * Growth Direct(®) supports faster microbial testing results and strengthens data integrity by automating testing steps and reducing manual transcription * Advances Merck KGaA, Darmstadt, Germany’s strategic focus on integrated workflow solutions Merck KGaA, Darmstadt, Germany, a leading science and technology company, has signed a definitive agreement to acquire Rapid Micro Biosystems, Inc. (Nasdaq: RPID). Rapid Micro Biosystems provides instruments, consumables, software and services that automate microbial quality-control testing in pharmaceutical manufacturing. The proposed acquisition would advance Merck KGaA, Darmstadt, Germany’s strategic focus on integrated workflows by bringing Rapid Micro Biosystems’ Growth Direct(®) platform together with its complementary pharmaceutical quality-control portfolio. Merck KGaA, Darmstadt, Germany's Life Science business operates as MilliporeSigma in the United States and Canada.
Get started
Create a free account to read the full story.
